PE20080353A1 - SALTS OF 8 - [{1- (3,5-BIS- (TRIFLUOROMETIL) PHENYL) -ETOXY} -METIL] -8-PHENYL-1,7-DIAZA-ESPIRO [4,5] DECAN-2-ONA AND PROCESS OF PREPARING THEM - Google Patents

SALTS OF 8 - [{1- (3,5-BIS- (TRIFLUOROMETIL) PHENYL) -ETOXY} -METIL] -8-PHENYL-1,7-DIAZA-ESPIRO [4,5] DECAN-2-ONA AND PROCESS OF PREPARING THEM

Info

Publication number
PE20080353A1
PE20080353A1 PE2007000415A PE2007000415A PE20080353A1 PE 20080353 A1 PE20080353 A1 PE 20080353A1 PE 2007000415 A PE2007000415 A PE 2007000415A PE 2007000415 A PE2007000415 A PE 2007000415A PE 20080353 A1 PE20080353 A1 PE 20080353A1
Authority
PE
Peru
Prior art keywords
phenyl
espiro
etoxy
decan
ona
Prior art date
Application number
PE2007000415A
Other languages
Spanish (es)
Inventor
Mengwei Hu
Sunil Paliwal
Neng-Yang Shih
Frank B Guenter
Ingrid Mergelsberg
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20080353A1 publication Critical patent/PE20080353A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIERE A FORMAS SALINAS CRISTALINAS DEL COMPUESTO (5S,8S)-8-[{(1R)-1-(3,5-BIS-(TRIFLUOROMETIL)FENIL-ETOXI}-METIL]-8-FENIL-1,7-DIAZA-ESPIRO[4,5]DECAN-2-ONA DE FORMULA (I), SIENDO SELECCIONADAS LA SAL CRISTALINA DE ESILATO QUE PRESENTA EL SIGUIENTES PATRON DE DIFRACCION EXPRESADOS EN ANGULOS DE DIFRACCION (2?) DE: 11.4, 12.8, 20.0, 21.2; LA SAL CRISTALINA DE OXILATO PRESENTA EL SIGUIENTE PATRON DE DIFRACCION (EXPRESADOS EN 2?) DE: 5.6, 19.8, 21.0, 22.8; LA SAL CRISTALINA DE MESILATO PRESENTA EL SIGUIENTE PATRON DE DIFRACCION: 4.7, 9.5, 19.2, 20.9; ASI TAMBIEN ES IDENTIFICADA LA SAL CRISTALINA DE MALEATO; ENTRE OTRAS SALES. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA; DICHO COMPUESTO ES UN ANTAGONISTA DEL RECEPTOR NK-1, POR LO QUE ES UTIL EN EL LA TERAPIA ANTINAUSEA Y ANTIEMESISREFERS TO CRYSTALLINE SALT FORMS OF THE COMPOUND (5S, 8S) -8 - [{(1R) -1- (3,5-BIS- (TRIFLUOROMETHYL) PHENYL-ETOXY} -Methyl] -8-PHENYL-1,7- DIAZA-ESPIRO [4,5] DECAN-2-ONA OF FORMULA (I), BEING SELECTED THE CRYSTALLINE ESILATE SALT THAT PRESENTS THE FOLLOWING PATTERN OF DIFFRACTION EXPRESSED IN ANGULES OF DIFRACTION (2?) OF: 11.4, 12.8, 20.0, 21.2; THE CRYSTALLINE SALT OF OXYLATE PRESENTS THE FOLLOWING PATTERN OF DIFFRACTION (EXPRESSED IN 2?) OF: 5.6, 19.8, 21.0, 22.8; THE CRYSTALLINE SALT OF MESILATE PRESENTS THE FOLLOWING PATTERN OF DIFFRACTION: 4.7, 9.5, 19.2, 20.9; SO CRYSTALINE MALEATE SALT IS ALSO IDENTIFIED; AMONG OTHER SALTS. IT ALSO REFERS TO A PREPARATION PROCEDURE AND A PHARMACEUTICAL COMPOSITION; SUCH COMPOUND IS AN ANTAGONIST OF THE NK-1 RECEPTOR, SO IT IS USEFUL IN ANTIEM THERAPY

PE2007000415A 2006-04-05 2007-04-04 SALTS OF 8 - [{1- (3,5-BIS- (TRIFLUOROMETIL) PHENYL) -ETOXY} -METIL] -8-PHENYL-1,7-DIAZA-ESPIRO [4,5] DECAN-2-ONA AND PROCESS OF PREPARING THEM PE20080353A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US78951306P 2006-04-05 2006-04-05

Publications (1)

Publication Number Publication Date
PE20080353A1 true PE20080353A1 (en) 2008-04-25

Family

ID=38470135

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000415A PE20080353A1 (en) 2006-04-05 2007-04-04 SALTS OF 8 - [{1- (3,5-BIS- (TRIFLUOROMETIL) PHENYL) -ETOXY} -METIL] -8-PHENYL-1,7-DIAZA-ESPIRO [4,5] DECAN-2-ONA AND PROCESS OF PREPARING THEM

Country Status (5)

Country Link
AR (1) AR060352A1 (en)
CL (1) CL2007000947A1 (en)
PE (1) PE20080353A1 (en)
TW (1) TW200806666A (en)
WO (1) WO2007114922A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2662373A1 (en) 2006-04-05 2013-11-13 OPKO Health, Inc. Salts of 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor
AR066191A1 (en) 2007-03-22 2009-08-05 Schering Corp PROCESS AND INTERMEDIARIES FOR THE SYNTHESIS OF COMPOUNDS 8- [(1- (3,5- BIS- (TRIFLUOROMETIL) PHENYL) - ETOXI) - METAL] - 8 PHENYL - 1,7- DIAZA - ESPIRO (4, 5) DECAN - 2 ONA
PT2346823E (en) 2008-09-05 2015-11-26 Opko Health Inc Intermediates for the synthesis of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds
CN105017251B (en) * 2015-06-30 2018-06-29 齐鲁制药有限公司 A kind of Preparation Method And Their Intermediate of nk 1 receptor antagonist

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20030762A1 (en) * 2001-12-18 2003-09-05 Schering Corp HETEROCYCLIC COMPOUNDS AS NK1 ANTAGONISTS
EP1706116A1 (en) * 2003-12-22 2006-10-04 Schering Corporation Pharmaceutical compositions

Also Published As

Publication number Publication date
TW200806666A (en) 2008-02-01
AR060352A1 (en) 2008-06-11
CL2007000947A1 (en) 2008-01-25
WO2007114922A2 (en) 2007-10-11
WO2007114922A3 (en) 2008-01-17

Similar Documents

Publication Publication Date Title
PE20120545A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING FORM I SALT CRYSTALLINE HYDROCHLORIDE MONOHYDRATE OF (5S, 8S) -8 - [{(1R) -1- (3,5-BIS- (TRIFLUOROMETIL) PHENYL) -ETOXY} -METIL] -8 -PHENYL-1,7-DIAZASPIRO [4,5] DECAN-2-ONA
PE20081650A1 (en) COMBINATIONS INCLUDING FORMOTEROL AND SALMETEROL AND SALTS OF 3 (R) - (2-HYDROXY-2,2-DITIEN-2-ILACETOXY) -1- (3-PHENOXYPROPYL) -1-AZONIABICICLO [2,2,2] OCTANE
PE20081891A1 (en) TABLET FORMULATIONS CONTAINING SALTS OF 8 - [{1- (3,5-BIS- (TRIFLUOROMETIL) PHENYL) -ETOXY} -METIL] -8-PHENYL-1,7-DIAZA-SPIRO [4.5] DECAN-2- ONA AND TABLETS MADE FROM THESE
WO2012101065A3 (en) Pyrimidine biaryl amine compounds and their use as cdk9 inhibitors
EA201001013A1 (en) BIS (SULFONILAMINO) DERIVATIVES FOR USE IN THERAPY
CO6290644A2 (en) KAPPA SELECTIVE OPIOID RECEIVER ANTAGONIST.
EA201000805A1 (en) BIS- (SULFONILAMINO) DERIVATIVES IN THERAPY 066
MX2011011156A (en) Diamide compounds having muscarinic receptor antagonist and î²2 adrenergic receptor agonist activity.
CL2012001517A1 (en) Divalent and heterocyclic compounds linked by nicotine related oxa; methods of preparing them; agrochemical composition comprising said compounds.
AR056014A1 (en) COMPOUND 3-AMINOCARBAZOL, PHARMACEUTICAL COMPOSITION CONTAINING IT AND PROCEDURE FOR THE PREPARATION OF THE SAME
PE20080054A1 (en) PHARMACEUTICAL SALTS FORMULATIONS OF 8- [1- (3,5-BIS- (TRIFLOUROMETHYL) PHENYL) -ETOXIMETHYL] -8-PHENYL-1,7-DIAZA-SPIRO [4,5] DECAN-2-ONA
EA200702161A1 (en) CRYSTAL FORM OF A QUINOLINON-CARBOXAMIDE COMPOUND
UY32156A (en) SUBSTITUTED DERIVATIVES OF THE N2 - [1- (5 - FLUOROPIRIMIDIN -2-IL) ETIL] - N4 - (1-METHYL - 1H-IMIDAZOL - 4 - IL)) - PYRIMIDINE - 2,4 - DIAMINES AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS , PREPARATION PROCESS, COMPOSITIONS CONTAINING THEM AND APPLICATIONS.
PE20140099A1 (en) DERIVATIVES OF AZETIDINE AND CYCLOBUTANE AS JAK INHIBITORS
PE20080353A1 (en) SALTS OF 8 - [{1- (3,5-BIS- (TRIFLUOROMETIL) PHENYL) -ETOXY} -METIL] -8-PHENYL-1,7-DIAZA-ESPIRO [4,5] DECAN-2-ONA AND PROCESS OF PREPARING THEM
EA201101398A1 (en) SUBSTITUTED PIPERIDINE AS AN ANTAGONIST CCR3
AR058904A1 (en) IMPROVED PROCESS FOR THE PREPARATION OF A DERIVATIVE OF 5H-PIRROLO [3,4-B] OPTICALLY ACTIVE PIRAZINE
SI2875011T1 (en) 5-ht3 receptor antagonists
BRPI0519709A2 (en) tetraline and indane derivatives and their use as 5-ht antagonists
TW200714587A (en) Biphenyl compounds useful as muscarinic receptor antagonists
AR068187A1 (en) CRYSTAL FORM OF A SYNTHETIC INTERMEDIARY FOR THE PREPARATION OF A DPP-IV INHIBITOR
CO6430439A2 (en) SPHINGOSINE RECEPTOR AGONISTS -1- PHOSPHATE
UY31672A1 (en) "MUSCARINIC RECEPTORS AGONISTS PHARMACEUTICAL COMPOSITIONS METHODS OF TREATMENT OF THE SAME, AND PROCEDURES FOR THEIR PREPARATION"
WO2012176218A8 (en) Process for preparing rosuvastatin calcium through novel amine salt
AR075160A1 (en) DERIVATIVES OF ARIL AND / OR HETEROARIL PIPERIDINES REPLACED, MEDICINES THAT CONTAIN THEM, PROCESS TO PREPARE THEM AND USE OF THE SAME FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS.

Legal Events

Date Code Title Description
FD Application declared void or lapsed